Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.

@article{Hansen1991AclarubicinPC,
  title={Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.},
  author={Ole Paaske Hansen and Jens Pedersen-Bjergaard and J\orgen Ellegaard and Hans Brincker and Anne Marie Boesen and Bjarne Egelund Christensen and Aage Drivsholm and Erik Hippe and Herbert Jans and Klaus B. Jensen},
  journal={Leukemia},
  year={1991},
  volume={5 6},
  pages={
          510-6
        }
}
A regimen of aclarubicin (ACR) of 75 mg/m2 daily for 3 days plus a continuous intravenous infusion of cytosine arabinoside (ara-C) of 100 mg/m2 per day for 7 days was compared with daunorubicin (DNR) 45 mg/m2/day for 3 days plus ara-C for 7 days as first-line chemotherapy of de novo acute myeloid leukemia (AML) in a randomized, nationwide Danish study. A total of 180 patients aged between 17 and 65 years were entered onto the protocol. Patients who achieved complete remission (CR) were given… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 18 citations